Unknown

Dataset Information

0

Quantitation of pretreatment serum interferon-?-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.


ABSTRACT: UNLABELLED:Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Quantitation of interferon-?-inducible protein-10 (IP-10) may also differentiate antiviral response. We evaluated IP-10 levels in pretreatment serum from 115 nonresponders and 157 sustained responders in the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C cohort, including African American (AA) and Caucasian American (CA) patients. Mean IP-10 was lower in sustained responders compared with nonresponders (437 ± 31 vs 704 ± 44 pg/mL, P < 0.001), both in AA and CA patients. The positive predictive value of low IP-10 levels (<600 pg/mL) for SVR was 69%, whereas the negative predictive value of high IP-10 levels (>600 pg/mL) was 67%. We assessed the combination of pretreatment IP-10 levels with IL28B genotype as predictors of treatment response. The IL28B polymorphism rs12979860 was tested in 210 participants. The CC, CT, and TT genotypes were found in 30%, 49%, and 21% of patients, respectively, with corresponding SVR rates of 87%, 50%, and 39% (P < 0.0001). Serum IP-10 levels within the IL28B genotype groups provided additional information regarding the likelihood of SVR (P < 0.0001). CT carriers with low IP-10 had 64% SVR versus 24% with high IP-10. Similarly, a higher SVR rate was identified for TT and CC carriers with low versus high IP-10 (TT, 48% versus 20%; CC, 89% versus 79%). IL28B genotype and baseline IP-10 levels were additive but independent when predicting SVR in both AA and CA patients. CONCLUSION:When IL28B genotype is combined with pretreatment serum IP-10 measurement, the predictive value for discrimination between SVR and nonresponse is significantly improved, especially in non-CC genotypes. This relationship warrants further investigation to elucidate the mechanisms of antiviral response and prospective validation.

SUBMITTER: Darling JM 

PROVIDER: S-EPMC3083026 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response.

Darling Jama M JM   Aerssens Jeroen J   Fanning Gregory G   McHutchison John G JG   Goldstein David B DB   Thompson Alexander J AJ   Shianna Kevin V KV   Afdhal Nezam H NH   Hudson Michael L ML   Howell Charles D CD   Talloen Willem W   Bollekens Jacques J   De Wit Mieke M   Scholliers Annick A   Fried Michael W MW  

Hepatology (Baltimore, Md.) 20110101 1


<h4>Unlabelled</h4>Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Quantitation of interferon-γ-inducible protein-10 (IP-10) may also differentiate antiviral response. We evaluated IP-10 levels in pretreatment serum from 115 nonresponders and 157 sustained responders in the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C cohort, including African Am  ...[more]

Similar Datasets

| S-EPMC3663887 | biostudies-literature
| S-EPMC7124215 | biostudies-literature
| S-EPMC7605464 | biostudies-literature
| S-EPMC2783369 | biostudies-literature
| S-EPMC4339676 | biostudies-literature
| S-EPMC4900731 | biostudies-literature
| S-EPMC4229256 | biostudies-literature
| S-EPMC4695043 | biostudies-literature
| S-EPMC3429646 | biostudies-literature
| S-EPMC5574888 | biostudies-other